Dendreon Corp. DNDN Stock Halted FDA Approval

Shares of Dendreon Corp. (DNDN) have been halted and the company just announced they have received FDA Approval for Provenge.

FDA clears Dendreon's prostate cancer vaccine.

Before the stock halt, Dendreon's stock traded above $45 per share. When DNDN reopens for trading this afternoon, I expect shares to trade between $50-$60.


Today's Biggest Stock Market Gainers - Top 2010 Stock Gainers - Top 2010 Penny Stocks - Top 2009 Stock Gainers - Top 2009 Penny Stocks - Hot OTC Stocks - Stocks for 2010

For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free

Dendreon DNDN Stock Halted 4/28/09 April 28, 2009

Dendreon ( DNDN ) stock was just halted after completely tanking. I think there was either a leak or a trading glitch but I'm pretty sure all trades will be cancelled one minute prior to the trading halt

I will post the data news on provenge when it comes out but feel free to discuss Dendreon Stock at http://stockstobuy.org

Provenge News

Increased extended survival 4.1 more months ( very good news )

http://investor.dendreon.com/releasedetail.cfm?ReleaseID=380042

Trading probably won't resume until 5:30pm tonight atleast

Today's Biggest Stock Market Gainers - Top 2009 Stock Gainers - Top 2009 Penny Stocks

For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free

Dendreon DNDN Stock April 13 2009 4/13/09

Shares of Dendreon ( DNDN ) are soaring in pre market trading this morning hitting $9.00 at one point on no news. Well, I assume news was leaked because I cannot find DNDN news anywhere. What I think is happening is news has been confirmed that Dendreon will release data at the American Urological Association (AUA) conference at the end of the month. I'm sure some kind of news will be released later in the day stating this.

Click Here for my previous article on DNDN

For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free